What is Lexeo Therapeutics Earnings Power Value (EPV)?
As of Sep24, Lexeo Therapeutics's earnings power value is $4.43. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Lexeo Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for Lexeo Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics Earnings Power Value (EPV) Chart
|
Lexeo Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
|
Lexeo Therapeutics Quarterly Data
|
|
Dec20 |
Dec21 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
Jun24 |
Sep24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Lexeo Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, Lexeo Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexeo Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Lexeo Therapeutics's Earnings Power Value (EPV) falls into.
Lexeo Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Lexeo Therapeutics Business Description
Traded in Other Exchanges
N/A
Address
345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Executives
| Paula H Cholmondeley |
director |
221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991 |
| Richard Nolan Townsend |
director, officer: Chief Executive Officer |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Lundbeckfond Invest A/s |
10 percent owner |
SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100 |
| Longitude Capital Partners Iv, Llc |
10 percent owner |
2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
| Omega Fund Vi Gp, L.p. |
10 percent owner |
888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
| Omega Fund Vi, L.p. |
10 percent owner |
888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
| Jenny Robertson |
officer: Chief Legal and Admin. Officer |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Paul Mccormac |
officer: Chief Technical Officer |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Bernard Davitian |
director |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Eric Adler |
officer: Chief Scientific Officer |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Brenda Cooperstone |
director |
C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Longitude Venture Partners Iv, L.p. |
10 percent owner |
2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
| Omega Fund Vi Gp Manager, Ltd. |
10 percent owner |
888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
| Reinaldo M Diaz |
director |
C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022 |
| Mette Kirstine Agger |
director |
C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830 |
Lexeo Therapeutics Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LXEO has been successfully added to your